EFSA confirms German glucosamine anticoagulant concerns

Related tags Warfarin

EFSA confirms German glucosamine anticoagulant concerns
The European Food Safety Authority (EFSA) has confirmed that joint health nutrient glucosamine can pose health risks to those taking anti-blood clotting drugs, after the issue was raised some years ago by German authorities.

"Glucosamine can amplify the anti-blood clotting effects of drugs and thus lead to haemorrhages," ​said German Federal Institute for Risk Assessment (BfR) BfR president, professor Dr. Dr. Andreas Hensel.

The BfR added: “In agreement with the BfR’s assessment, EFSA comes to the conclusion that there is evidence for the risk of interaction between glucosamine and coumarin anticoagulants.

Glucosamine can boost the anti-blood clotting effects of these drugs, i.e. these effects can suddenly be stronger than expected. One possible consequence are haemorrhages. In the majority of reported cases, the increases detected were symptomless changes in laboratory values. In some cases, however, haemorrhages did occur in various organs, in one case with the consequence of a severe cerebral haemorrhage. "

The EFSA opinion

In its opinion on the matter EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) concluded there was risk albeit inconclusive. It stated:There is insufficient information to conclude on a mechanism for an interaction between glucosamine and coumarin anticoagulants. There are also insufficient data in the case reports to derive a dose-response relationship for glucosamine and to assess the level of risk.“

The Panel concludes that there is evidence for a risk of interaction between glucosamine and coumarin anticoagulants in some individuals that could lead to an increased INR, and, that this could further lead to haemorrhage. The level of risk cannot be ascertained because of insufficient data.“

The opinion can be found here.

Related news

Show more

Related products

show more

MenaQ7® Matrix Enables Next-Level Formulations

MenaQ7® Matrix Enables Next-Level Formulations

Gnosis by Lesaffre | 01-Feb-2023 | Technical / White Paper

Enhancing the protection of the MK-7 molecule is crucial for creating complex formulations that will truly impact health. MenaQ7® Matrix offers the first...

Give joint health consumers what they want

Give joint health consumers what they want

Lonza | 17-Jan-2023 | Insight Guide

It’s no secret the pandemic had a profound effect on the way we live and move. Consumers of all ages now want to get back to doing the things they love,...

Fast, Low-Dose, Scientifically Supported MOBILITY.

Fast, Low-Dose, Scientifically Supported MOBILITY.

PLT Health Solutions | 30-Nov-2022 | Product Brochure

AprèsFlex® 5-Day Joint Support is one of the world’s best-selling joint health ingredients – with studies that demonstrate efficacy starting at 5 days...

Do you need a Bone & Joint Guidebook?

Do you need a Bone & Joint Guidebook?

Ingredients4u AG | 15-Nov-2022 | Product Brochure

Ingregdients4U is an engagement ingredients procurement platform, offering unrivalled directory of products sourced from world-class ingredient brands...

1 comment

Glucosamine safety concerns

Posted by David Kinlay,

Are they safe overall? They are widespread on the market presently.

Report abuse

Follow us

Products

View more

Webinars